Fuchsberger T, Stockwell I, Woods M, Brzosko Z, Greger I, Paulsen O
Elife. 2025; 13.
PMID: 40063079
PMC: 11893101.
DOI: 10.7554/eLife.100822.
Fleige L, Capellino S
Biol Sex Differ. 2025; 16(1):8.
PMID: 39901238
PMC: 11789415.
DOI: 10.1186/s13293-025-00689-5.
Zhou Y, Tang J, Weng M, Zhang H, Lai M
Adv Sci (Weinh). 2024; 12(6):e2413953.
PMID: 39679842
PMC: 11809390.
DOI: 10.1002/advs.202413953.
Shang L, Yang F, Chen Q, Dai Z, Yang G, Zeng X
J Anim Sci Biotechnol. 2024; 15(1):156.
PMID: 39533384
PMC: 11559059.
DOI: 10.1186/s40104-024-01115-3.
Haakenson C, Balthazart J, VanRyzin J, Marquardt A, Ashton S, McCarthy M
J Comp Neurol. 2024; 532(10):e25675.
PMID: 39387367
PMC: 11548801.
DOI: 10.1002/cne.25675.
CHL1 depletion affects dopamine receptor D2-dependent modulation of mouse behavior.
Fernandes L, Kleene R, Congiu L, Freitag S, Kneussel M, Loers G
Front Behav Neurosci. 2023; 17:1288509.
PMID: 38025382
PMC: 10665519.
DOI: 10.3389/fnbeh.2023.1288509.
Dopamine Receptor Type 2-Expressing Medium Spiny Neurons in the Ventral Lateral Striatum Have a Non-REM Sleep-Induce Function.
Kato T, Tanaka K, Natsubori A
eNeuro. 2023; 10(9).
PMID: 37704366
PMC: 10540673.
DOI: 10.1523/ENEURO.0327-23.2023.
Sepsis sensitizes behavioural amphetamine responses while inducing inflammatory and neurotrophic vulnerability in the cecal ligation and puncture model.
Valvassori S, Possamai-Della T, Aguiar-Geraldo J, SantAna R, Dal-Pont G, Pescador B
Eur J Neurosci. 2023; 59(6):1153-1168.
PMID: 37350331
PMC: 10746835.
DOI: 10.1111/ejn.16064.
Dopamine D Agonists: First Potential Treatment for Late-Stage Parkinson's Disease.
Lewis M, Van Scoy L, De Jesus S, Hakun J, Eslinger P, Fernandez-Mendoza J
Biomolecules. 2023; 13(5).
PMID: 37238699
PMC: 10216182.
DOI: 10.3390/biom13050829.
Specificity of striatal dopamine D system in humans: implications for clinical use of D receptor-agonists in Parkinson's disease.
Goto S
Front Hum Neurosci. 2023; 17:1178616.
PMID: 37180553
PMC: 10169585.
DOI: 10.3389/fnhum.2023.1178616.
Role of dopamine agonists in Parkinson's disease therapy.
Woitalla D, Buhmann C, Hilker-Roggendorf R, Hoglinger G, Koschel J, Muller T
J Neural Transm (Vienna). 2023; 130(6):863-873.
PMID: 37165120
DOI: 10.1007/s00702-023-02647-0.
Cortical dopamine D5 receptors regulate neuronal circuit oscillatory activity and memory in rats.
Albeely A, Nolan C, Rasmussen D, Bailey C, Perreault M
CNS Neurosci Ther. 2023; 29(9):2469-2480.
PMID: 37076975
PMC: 10401150.
DOI: 10.1111/cns.14210.
Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D, Balasubramanian S, Krishnamurthy P, Sola P, Rymbai E
Cell Mol Neurobiol. 2023; 43(6):2713-2741.
PMID: 37074485
PMC: 11410141.
DOI: 10.1007/s10571-023-01349-1.
Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine D and D Receptors and Their Impact on Behavioral Sensitization.
Kim K
Int J Mol Sci. 2023; 24(7).
PMID: 37047716
PMC: 10095578.
DOI: 10.3390/ijms24076742.
Regulation and modulation of biogenic amine neurotransmission in and .
Rosikon K, Bone M, Lawal H
Front Physiol. 2023; 14:970405.
PMID: 36875033
PMC: 9978017.
DOI: 10.3389/fphys.2023.970405.
Segregation of D1 and D2 dopamine receptors in the striatal direct and indirect pathways: An historical perspective.
Gerfen C
Front Synaptic Neurosci. 2023; 14:1002960.
PMID: 36741471
PMC: 9892636.
DOI: 10.3389/fnsyn.2022.1002960.
Modulating brain integrative actions as a new perspective on pharmacological approaches to neuropsychiatric diseases.
Marcoli M, Agnati L, Franco R, Cortelli P, Anderlini D, Guidolin D
Front Endocrinol (Lausanne). 2023; 13:1038874.
PMID: 36699033
PMC: 9868467.
DOI: 10.3389/fendo.2022.1038874.
Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein.
Dinda B, Das B, Biswas S, Sharma H, Armstrong C, Yedlapudi D
Bioorg Med Chem. 2022; 78:117131.
PMID: 36571976
PMC: 9898996.
DOI: 10.1016/j.bmc.2022.117131.
Developing Photoaffinity Probes for Dopamine Receptor D to Determine Targets of Parkinson's Disease Drugs.
Kim S, Doukmak E, Flax R, Gray D, Zirimu V, de Jong E
ACS Chem Neurosci. 2022; 13(20):3008-3022.
PMID: 36183275
PMC: 9585581.
DOI: 10.1021/acschemneuro.2c00544.
Dopamine, Erectile Function and Male Sexual Behavior from the Past to the Present: A Review.
Melis M, Sanna F, Argiolas A
Brain Sci. 2022; 12(7).
PMID: 35884633
PMC: 9312911.
DOI: 10.3390/brainsci12070826.
